Cargando…
Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis
Cystic fibrosis (CF) is a lethal monogenic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that entails the (diagnostic) increase in sweat electrolyte concentrations, progressive lung disease with chronic inflammation and recurrent bacterial infecti...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791443/ https://www.ncbi.nlm.nih.gov/pubmed/26976279 http://dx.doi.org/10.1186/s40348-016-0040-z |
_version_ | 1782421089395146752 |
---|---|
author | Esposito, Speranza Tosco, Antonella Villella, Valeria R. Raia, Valeria Kroemer, Guido Maiuri, Luigi |
author_facet | Esposito, Speranza Tosco, Antonella Villella, Valeria R. Raia, Valeria Kroemer, Guido Maiuri, Luigi |
author_sort | Esposito, Speranza |
collection | PubMed |
description | Cystic fibrosis (CF) is a lethal monogenic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that entails the (diagnostic) increase in sweat electrolyte concentrations, progressive lung disease with chronic inflammation and recurrent bacterial infections, pancreatic insufficiency, and male infertility. Therapies aimed at restoring the CFTR defect have emerged. Thus, a small molecule which facilitates chloride channel opening, the potentiator Ivacaftor, has been approved for the treatment of CF patients bearing a particular class of rare CFTR mutations. However, small molecules that directly target the most common misfolded CFTR mutant, F508del, and improve its intracellular trafficking in vitro, have been less effective than expected when tested in CF patients, even in combination with Ivacaftor. Thus, new strategies are required to circumvent the F508del-CFTR defect. Airway and intestinal epithelial cells from CF patients bearing the F508del-CFTR mutation exhibit an impressive derangement of cellular proteostasis, with oxidative stress, overactivation of the tissue transglutaminase (TG2), and disabled autophagy. Proteostasis regulators such as cysteamine can rescue and stabilize a functional F508del-CFTR protein through suppressing TG2 activation and restoring autophagy in vivo in F508del-CFTR homozygous mice, in vitro in CF patient-derived cell lines, ex vivo in freshly collected primary patient’s nasal cells, as well as in a pilot clinical trial involving homozygous F508del-CFTR patients. Here, we discuss how the therapeutic normalization of defective proteostasis can be harnessed for the treatment of CF patients with the F508del-CFTR mutation. |
format | Online Article Text |
id | pubmed-4791443 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-47914432016-04-09 Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis Esposito, Speranza Tosco, Antonella Villella, Valeria R. Raia, Valeria Kroemer, Guido Maiuri, Luigi Mol Cell Pediatr Mini Review Cystic fibrosis (CF) is a lethal monogenic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that entails the (diagnostic) increase in sweat electrolyte concentrations, progressive lung disease with chronic inflammation and recurrent bacterial infections, pancreatic insufficiency, and male infertility. Therapies aimed at restoring the CFTR defect have emerged. Thus, a small molecule which facilitates chloride channel opening, the potentiator Ivacaftor, has been approved for the treatment of CF patients bearing a particular class of rare CFTR mutations. However, small molecules that directly target the most common misfolded CFTR mutant, F508del, and improve its intracellular trafficking in vitro, have been less effective than expected when tested in CF patients, even in combination with Ivacaftor. Thus, new strategies are required to circumvent the F508del-CFTR defect. Airway and intestinal epithelial cells from CF patients bearing the F508del-CFTR mutation exhibit an impressive derangement of cellular proteostasis, with oxidative stress, overactivation of the tissue transglutaminase (TG2), and disabled autophagy. Proteostasis regulators such as cysteamine can rescue and stabilize a functional F508del-CFTR protein through suppressing TG2 activation and restoring autophagy in vivo in F508del-CFTR homozygous mice, in vitro in CF patient-derived cell lines, ex vivo in freshly collected primary patient’s nasal cells, as well as in a pilot clinical trial involving homozygous F508del-CFTR patients. Here, we discuss how the therapeutic normalization of defective proteostasis can be harnessed for the treatment of CF patients with the F508del-CFTR mutation. Springer Berlin Heidelberg 2016-03-14 /pmc/articles/PMC4791443/ /pubmed/26976279 http://dx.doi.org/10.1186/s40348-016-0040-z Text en © Esposito et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Mini Review Esposito, Speranza Tosco, Antonella Villella, Valeria R. Raia, Valeria Kroemer, Guido Maiuri, Luigi Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis |
title | Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis |
title_full | Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis |
title_fullStr | Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis |
title_full_unstemmed | Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis |
title_short | Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis |
title_sort | manipulating proteostasis to repair the f508del-cftr defect in cystic fibrosis |
topic | Mini Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791443/ https://www.ncbi.nlm.nih.gov/pubmed/26976279 http://dx.doi.org/10.1186/s40348-016-0040-z |
work_keys_str_mv | AT espositosperanza manipulatingproteostasistorepairthef508delcftrdefectincysticfibrosis AT toscoantonella manipulatingproteostasistorepairthef508delcftrdefectincysticfibrosis AT villellavaleriar manipulatingproteostasistorepairthef508delcftrdefectincysticfibrosis AT raiavaleria manipulatingproteostasistorepairthef508delcftrdefectincysticfibrosis AT kroemerguido manipulatingproteostasistorepairthef508delcftrdefectincysticfibrosis AT maiuriluigi manipulatingproteostasistorepairthef508delcftrdefectincysticfibrosis |